** Shares in Humana fall 3.7% while Clover Health Investment gain 4.5% in premarket trade
** CLOV's PPO Medicare Advantage plans earn a 4-star rating for 2025
** Humana is "likely to track in line" with its estimates last week, which pointed to only a quarter of its members remaining enrolled in 2025 for its 4+ rating plans, compared with 94% in 2024, Oppenheimer said in a note
** The U.S. government said on Friday that 62% of people currently enrolled in Medicare Advantage plans that cover prescription drugs are covered by plans rated four or more stars down from 74% last year
** About 40% of plans being offered are four stars or higher, down from 42% in 2024, it added
(Reporting by Paolo Laudani)
((Paolo.laudani@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.